Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine

Charalambos D. Partidos; Joanna Paykel; James Weger; Erin M. Borland; Ann M. Powers; Robert Seymour; Scott C. Weaver; Dan T. Stinchcomb; Jorge E. Osorio

doi:10.1016/j.vaccine.2012.04.099

Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine

Charalambos D. Partidos, Joanna Paykel, James Weger, Erin M. Borland, Ann M. Powers, Robert Seymour, Scott C. Weaver, Dan T. Stinchcomb, Jorge E. Osorio

Microbiology And Immunology

Research output: Contribution to journal › Article › peer-review

78 Scopus citations

Abstract

Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o'nyong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease.

Original language	English (US)
Pages (from-to)	4638-4643
Number of pages	6
Journal	Vaccine
Volume	30
Issue number	31
DOIs	https://doi.org/10.1016/j.vaccine.2012.04.099
State	Published - Jun 29 2012

Keywords

A129 mice
Chikungunya virus (CHIKV)
Interferon (IFN)
Maternal-fetal immunity
O'nyong-nyong virus (ONNV)

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2012.04.099

Cite this

@article{37b3163f93b4449482e639d34a7529a7,

title = "Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine",

abstract = "Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o'nyong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease.",

keywords = "A129 mice, Chikungunya virus (CHIKV), Interferon (IFN), Maternal-fetal immunity, O'nyong-nyong virus (ONNV)",

author = "Partidos, {Charalambos D.} and Joanna Paykel and James Weger and Borland, {Erin M.} and Powers, {Ann M.} and Robert Seymour and Weaver, {Scott C.} and Stinchcomb, {Dan T.} and Osorio, {Jorge E.}",

note = "Funding Information: We gratefully thank Dr Jill Livengood and Laszlo Varga for providing the CHIKV/IRES vaccine. PLS was supported by NIH grant 5T32AI007536 , and this research was supported by NIH grant AI082202 .",

year = "2012",

month = jun,

day = "29",

doi = "10.1016/j.vaccine.2012.04.099",

language = "English (US)",

volume = "30",

pages = "4638--4643",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "31",

}

TY - JOUR

T1 - Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine

AU - Partidos, Charalambos D.

AU - Paykel, Joanna

AU - Weger, James

AU - Borland, Erin M.

AU - Powers, Ann M.

AU - Seymour, Robert

AU - Weaver, Scott C.

AU - Stinchcomb, Dan T.

AU - Osorio, Jorge E.

N1 - Funding Information: We gratefully thank Dr Jill Livengood and Laszlo Varga for providing the CHIKV/IRES vaccine. PLS was supported by NIH grant 5T32AI007536 , and this research was supported by NIH grant AI082202 .

PY - 2012/6/29

Y1 - 2012/6/29

N2 - Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o'nyong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease.

AB - Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o'nyong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease.

KW - A129 mice

KW - Chikungunya virus (CHIKV)

KW - Interferon (IFN)

KW - Maternal-fetal immunity

KW - O'nyong-nyong virus (ONNV)

UR - http://www.scopus.com/inward/record.url?scp=84861977697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861977697&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.04.099

DO - 10.1016/j.vaccine.2012.04.099

M3 - Article

C2 - 22583812

AN - SCOPUS:84861977697

SN - 0264-410X

VL - 30

SP - 4638

EP - 4643

JO - Vaccine

JF - Vaccine

IS - 31

ER -

Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this